{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-328784","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2026-07-31T20:50:54+00:00","discovered_at":"2026-07-31T20:52:00.371531+00:00","generated_at":"2026-07-31T20:52:07.475929+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Quince Therapeutics announces conditional CEO/COO resignations and appointments pending shareholder vote","bullets":["CEO Dirk Thye and COO Brendan Hannah tender conditional resignations effective two business days after Sept 25, 2026 special meeting, contingent on stockholder approval of three proposals.","Board conditionally appoints Brigette Roberts as CEO, John Militello as CFO, and Keith Fandrick as COO, effective at same time.","Board reduces size from 5 to 4 upon Thye's resignation; intends to appoint independent director.","Resignations and appointments tied to stockholder vote on conversion proposal, minimum price proposal, and authorized share increase to 275M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-328784","json":"https://secwatch.observer/filing/0001193125-26-328784.json","markdown":"https://secwatch.observer/filing/0001193125-26-328784.md","text":"https://secwatch.observer/filing/0001193125-26-328784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/0001193125-26-328784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/d160394d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-31T20:52:07.475929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a91a46b1a","claim":"Brendan Hannah resigned as Chief Operating Officer, Chief Business Officer and Chief Compliance Officer at Quince Therapeutics, Inc..","evidence_excerpt":"each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the “ Company ”), and a member of the Company’s board of directors (the “ Board ”), and Brendan Hannah, the Company’s Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, tendered conditional resignations from their positions with the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/0001193125-26-328784-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Operating Officer, Chief Business Officer and Chief Compliance Officer"}],"fact_type":"executive_change"},{"claim_id":"19d9804be9","claim":"John Militello was appointed as Chief Financial Officer at Quince Therapeutics, Inc..","evidence_excerpt":"John Militello, CPA , age 52, was conditionally appointed as the Company’s Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/0001193125-26-328784-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"1dfdcd5d91","claim":"Brigette Roberts was appointed as Chief Executive Officer at Quince Therapeutics, Inc..","evidence_excerpt":"Brigette Roberts, M.D. , age 50, was conditionally appointed as the Company’s Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/0001193125-26-328784-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"4f13a7a535","claim":"Dirk Thye resigned as Chief Executive Officer and Chief Medical Officer at Quince Therapeutics, Inc..","evidence_excerpt":"each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the “ Company ”), and a member of the Company’s board of directors (the “ Board ”), and Brendan Hannah, the Company’s Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, tendered conditional resignations from their positions with the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/0001193125-26-328784-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer and Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"5c19420cc3","claim":"Keith Fandrick was appointed as Chief Operating Officer at Quince Therapeutics, Inc..","evidence_excerpt":"Conditional Appointments of Brigette Roberts, John Militello and Keith Fandrick","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/0001193125-26-328784-index.htm","confidence":0.7,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}